首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   727427篇
  免费   45871篇
  国内免费   1305篇
耳鼻咽喉   9362篇
儿科学   23854篇
妇产科学   17940篇
基础医学   112865篇
口腔科学   20250篇
临床医学   65571篇
内科学   138204篇
皮肤病学   16391篇
神经病学   51299篇
特种医学   26307篇
外国民族医学   79篇
外科学   106633篇
综合类   15010篇
现状与发展   2篇
一般理论   167篇
预防医学   52491篇
眼科学   16994篇
药学   54786篇
  13篇
中国医学   2388篇
肿瘤学   43997篇
  2019年   5811篇
  2018年   8125篇
  2017年   6339篇
  2016年   7097篇
  2015年   7796篇
  2014年   10594篇
  2013年   15849篇
  2012年   21177篇
  2011年   22233篇
  2010年   13147篇
  2009年   12324篇
  2008年   20603篇
  2007年   22240篇
  2006年   22601篇
  2005年   21101篇
  2004年   20677篇
  2003年   19539篇
  2002年   19112篇
  2001年   36834篇
  2000年   37399篇
  1999年   30787篇
  1998年   8053篇
  1997年   6821篇
  1996年   7099篇
  1995年   6777篇
  1994年   6221篇
  1993年   5717篇
  1992年   23359篇
  1991年   23295篇
  1990年   22678篇
  1989年   22379篇
  1988年   20347篇
  1987年   19732篇
  1986年   18787篇
  1985年   17590篇
  1984年   12952篇
  1983年   10947篇
  1982年   6067篇
  1979年   11723篇
  1978年   8299篇
  1977年   6955篇
  1976年   6724篇
  1975年   7404篇
  1974年   8658篇
  1973年   8301篇
  1972年   7784篇
  1971年   7250篇
  1970年   6973篇
  1969年   6421篇
  1968年   5858篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
82.
83.
10 patients with CLL and 2 with CML were treated with gradually increasing doses of 1 alpha(OH)D3, up to 4 micrograms daily during 6 wk. 3 patients with preleukemia and 1 with myelofibrosis were treated with 2 micrograms daily of 1 alpha(OH)D3 for a prolonged period up to 17 wk. The treatment with 1 alpha (OH)D3 did not result in changes of disease parameters in any of the patients under study. Receptor studies for 1,25(OH)2D3 were performed in 8 CLL patients and revealed only 1 patient with increased specific receptor binding capacity. The maximum tolerable dose of 1 alpha(OH)D3 varied individually, but was in the range of 2-4 micrograms daily.  相似文献   
84.
Biliopancreatic diversion is a very effective method for weight reduction. In some instances it is too effective and needs to be revised.  相似文献   
85.
86.
In 1983, 1623 primary and secondary schoolchildren took part in a health survey which was organized by the Busselton Population Studies Group. Age, sex, weight, height and country of birth were recorded for each child. Where possible, the country of birth of parents and the occupation of the father were extracted from previous Busselton surveys of adults. Compared with Perth schoolchildren, the difference in the attained weight and height of Busselton children at any age was small. This was so even though the two communities differ in location (rural compared with metropolitan), in ethnic origin (mainly British compared with diverse origins) and, probably, in social-rank distribution. Data from the two communities showed that a similar small secular increase in height had occurred since 1970/1971. This increase averaged at 1.2 cm for children at each year of age in Busselton and 1.5 cm to 1.6 cm for children in Perth.  相似文献   
87.
88.
A novel approach for modelling the biological activity of organic molecules, which requires simultaneous consideration of the influence of all factors (topological, steric, hydrophobic, and electronic) that determine the bioactivity, is used to study the interaction of a series of benzoates with anti-p-(p'-azophenylazo)benzoate antibody. The results obtained suggest that this biological interaction proceeds by a two-step stereospecific mechanism. The first step requires a geometrical correspondence between the benzoates and the cavity in the biomacromolecule, which enables the pharmacophore to come into close contact with the receptor. The second step is the orbitally controlled electronic interaction between the active parts of the benzoates and the antibody. The electronic interaction results from pi-charge transfer from the pharmacophore to the biomacromolecule and from the formation of pi-complexes. A proposed mathematical model for this biological interaction exhibits some statistical advantages over existing models.  相似文献   
89.
90.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号